Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Skin Complications of Anti-TNF Therapy Common in IBD

Reuters Staff  |  July 31, 2015

NEW YORK (Reuters Health)—Dermatologic complications hit about one in five patients with inflammatory bowel disease (IBD) on anti-tumor necrosis factor (anti-TNF) therapy, leading to discontinuation of treatment, a French study finds. Dr. Laurent Peyrin-Biroulet, from University Hospital of Nancy, and colleagues note that dermatological complications of anti-TNF therapy are known to occur frequently in IBD…

Filed under:ConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:anti-TNF agentanti-tumor necrosis factorCrohn's diseaseinflammatory bowel diseaseskin disease

Maintaining Board Certification Has High Hidden Cost

Will Boggs, MD  |  July 30, 2015

NEW YORK (Reuters Health)—The American Board of Internal Medicine (ABIM) maintenance-of-certification (MOC) program could cost $5.7 billion in physicians’ time and fees over the next decade, according to a new model study. “We estimate that physicians will spend 33 million hours over 10 years to fulfill MOC requirements,” Dr. Dhruv S. Kazi from the University…

Filed under:Career DevelopmentCertificationProfessional Topics Tagged with:American Board of Internal Medicine (ABIM)CertificationMaintenance of Certification

U.S. Predicts 5.8% Average Rise in Healthcare Spending Through 2024

Caroline Humer  |  July 30, 2015

NEW YORK (Reuters)—The U.S. government expects healthcare spending to increase by 5.8% annually on average from 2014 through 2024 as more Americans gain insurance coverage and the improved economy drives patients to visit doctors and hospitals. The aging population’s higher healthcare costs will also push health spending higher starting in 2019, according to a study…

Filed under:Professional Topics Tagged with:agingHealth InsuranceObamacarespending

Healthcare Improving for Older Americans

Andrew M. Seaman  |  July 29, 2015

(Reuters Health)—The number of deaths, hospital stays and healthcare costs decreased among older Americans on Medicare over the past 15 years, according to a new study. “Although our health care system has its failings, we are making remarkable progress,” said Dr. Harlan Krumholz, the study’s lead author from Yale University in New Haven, Connecticut. “People…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:agingMedicaremortality rate

FDA Issues Stronger NSAIDs Warning

Michele B. Kaufman, PharmD, BCGP  |  July 29, 2015

The FDA revised its warning and labeling recommendations for antiinflammatory drugs because of a greater understanding of the increased risks they pose for stroke and myocardial infarction…

Filed under:AnalgesicsDrug Updates Tagged with:Drug SafetyFDAMyocardial infarctionnonsteroidal antiinflammatory drug (NSAID)NSAIDsstroke

Some Serious Drug Side Effects Not Reported to FDA Within 15 days

Lisa Rapaport  |  July 28, 2015

(Reuters Health)—Companies fail to report roughly one in 10 serious and unexpected medication side effects to the U.S. Food and Drug Administration (FDA) within a 15-day window specified by federal regulations to protect patient safety, a study finds. Drug manufacturers are also less likely to disclose serious adverse events within this window when patient deaths…

Filed under:Drug Updates Tagged with:adverse drug reactionDrug SafetyFDAInformed Consent

Anthem to Buy Cigna to Create Biggest U.S. Health Insurer

Ankur Banerjee  |  July 24, 2015

(Reuters)—Anthem Inc. said on Friday it would buy Cigna Corp. in a deal valued at $54.2 billion, creating the largest U.S. health insurer by membership. The deal—the biggest ever in the health insurance industry—comes three weeks after Aetna Inc agreed to buy Humana Inc for $37 billion and is part of an industry-wide consolidation following…

Filed under:Drug Updates Tagged with:Anthem Inc.Cigna Corp.Health Insurance

Main Fund for U.S. Medicare Program to Run Out of Money in 2030

Reuters Staff  |  July 22, 2015

WASHINGTON (Reuters)—A slowdown in healthcare spending has shored up the funding outlook for the federal program that pays elderly Americans’ hospital bills, trustees of the program said on Wednesday. The Medicare program’s trust fund for hospital care will run out of money in 2030 the trustees said in a report. That was the same year…

Filed under:Legislation & Advocacy Tagged with:federal fundingMedicaresocial security

Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website

Michele B. Kaufman, PharmD, BCGP  |  July 22, 2015

In a 25 month Phase 3 trial, abaloparatide-SC reduced the risk of new fractures in patients suffering from postmenopausal osteoporosis. Plus, the FDA launches a new drug safety website.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideFDAFracturesOsteoporosisosteoporosis treatmentsREMS

Fulfilling ‘Three Wishes’ Helps ICU Staff Honor Dying Patients

Randi Belisomo  |  July 18, 2015

(Reuters Health)—Doctors and nurses in a Canadian intensive care unit found that asking dying patients—or their families—to make three simple wishes, and then fulfilling those wishes, helped bring peace to the end-of-life process and ease grief. Patients and families were invited to participate in the “Three Wishes Project” after a decision was made to withdraw…

Filed under:Patient PerspectivePractice Support Tagged with:family functioninghospitalmortalitypatient care

  • « Previous Page
  • 1
  • …
  • 237
  • 238
  • 239
  • 240
  • 241
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences